1. Unraveling the role of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer by multi-omics analyses.
- Author
-
Lee, Seong, Park, Seongyeol, Yi, Shinae, Choi, Na, Lim, Mi, Chang, Jae, Won, Ho-Ryun, Kim, Je, Ko, Hye, Chung, Eun-Jae, Park, Young, Cho, Sun, Yu, Hyeong, Choi, June, Yeo, Min-Kyung, Yi, Boram, Yi, Kijong, Lim, Joonoh, Koh, Jun-Young, Lee, Min, Heo, Jun, Yoon, Sang, Kwon, Sung, Park, Jong-Lyul, Chu, In, Kim, Jin, Kim, Seon-Young, Shan, Yujuan, Liu, Lihua, Hong, Sung-A, Choi, Dong, Park, Junyoung, Ju, Young, Shong, Minho, Kim, Seon-Kyu, Koo, Bon, and Kang, Yea
- Abstract
The role of the serine/glycine metabolic pathway (SGP) has recently been demonstrated in tumors; however, the pathological relevance of the SGP in thyroid cancer remains unexplored. Here, we perform metabolomic profiling of 17 tumor-normal pairs; bulk transcriptomics of 263 normal thyroid, 348 papillary, and 21 undifferentiated thyroid cancer samples; and single-cell transcriptomes from 15 cases, showing the impact of mitochondrial one-carbon metabolism in thyroid tumors. High expression of serine hydroxymethyltransferase-2 (SHMT2) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is associated with low thyroid differentiation scores and poor clinical features. A subpopulation of tumor cells with high mitochondrial one-carbon pathway activity is observed in the single-cell dataset. SHMT2 inhibition significantly compromises mitochondrial respiration and decreases cell proliferation and tumor size in vitro and in vivo. Collectively, our results highlight the importance of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer and suggest that SHMT2 is a potent therapeutic target.
- Published
- 2024